OnCo
institutionsInstitution

Mayo Clinic

Consistently the top-ranked US hospital overall, with strong proton therapy and the first US carbon-ion centre under construction.

Mayo Clinic Comprehensive Cancer Center spans Rochester, Phoenix (#26), Jacksonville (#38, carbon-ion facility). Leaders in myeloma, lymphoma, and individualised medicine.

Location
Rochester, MN, US
Type
hospital
Newsweek 2026 oncology rank
#5
NCI designation
comprehensive
OnCo score
#9 · 102 points (55 Newsweek + 15 NCI + 32 from 16 linked objects) · ranking

Programmes

3top
  • Carbon-ion therapy (Jacksonville)
  • Myeloma
  • Proton therapy

People

7top
Cheryl L. Willman
Executive Director, Mayo Clinic Comprehensive Cancer Center
Leukaemia genomicsCancer center leadershipHealth disparities

Cheryl Willman is a leukaemia genomics pioneer who leads Mayo Clinic's cancer centre across its three sites.

Evanthia Galanis
Group Chair, Alliance for Clinical Trials in Oncology; Professor of Oncology, Mayo Clinic
Neuro-oncologyOncolytic virusesCooperative group trials

Evanthia Galanis is a brain tumour specialist who chairs one of the largest US clinical trial networks.

Mark R. Litzow
Professor of Medicine, Mayo Clinic; Chair, ECOG-ACRIN Leukemia Committee; Study Chair, E1910
Acute lymphoblastic leukaemiaImmunotherapyTransplant

Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.

Matthew P. Goetz
Professor of Oncology and Pharmacology; Co-leader, Women's Cancer Program, Mayo Clinic
Breast cancerPharmacogenomicsCDK4/6 inhibitors

Breast oncologist who led MONARCH 3 and studies how genetics shapes response to endocrine therapy.

S. Vincent Rajkumar
Professor of Medicine, Division of Hematology, Mayo Clinic
Multiple myelomaPlasma cell disordersDrug pricing

Myeloma expert who wrote the diagnostic criteria the field uses and a persistent critic of drug prices.

Shaji K. Kumar
Professor of Medicine; Chair, Myeloma, Amyloidosis and Dysproteinemia Group, Mayo Clinic
Multiple myelomaClinical trialsMRD

Myeloma trialist who led venetoclax and quadruplet studies and helped define MRD response criteria.

Tanios Bekaii-Saab
Professor of Medicine; Leader, GI Cancer Program, Mayo Clinic Arizona
Gastrointestinal oncologyColorectal cancerBiliary cancer

GI oncologist behind trials of KRAS, HER2, and FGFR-directed therapy in colorectal and bile duct cancer.

Connected

23top

Pages like this

not linked directly; found by shared links